From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer. Precise ...

Lung cancer is still one of the most common malignancies with a high global mortality rate with over 2 million cases confirmed by the World Health Organization in 2018. Although there has been ...

Broad enrollment criteria appear to have scuttled the trial, which was designed to test whether ctDNA could identify patients ...

This past year, the role of ctDNA testing has expanded to guide treatment decisions for providers and patients with cancer.

Scientists at City of Hope have collared a tricky culprit that helps cancer cells evade CAR T cell therapy. CAR T cell ...

A mathematical model shows that mutations that recur even modestly among cancer patients are cancer driving nucleotides that can be exhaustively identified to serve as targets of cancer therapy.

Scientists at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S.

Analyses of discovered cancer-driving nucleotides (CDNs) reveal their evolutionary, biochemical, and therapeutic characteristics that are often shared among multiple cancer types.

The spirometer (built-in 1846 by Hutchinson) measures ventilatory function (dynamic lung volumes and maximal flow rates). Miller 1996 [1]) shows a normal spirogram showing the measurements of forced ...